?
How can Clinical trials, Biomarkers signals be standardized across cohorts and sites without losing disease-stage sensitivity?
active
open question
Created: 2026-04-26T03:29:33
By: backfill_open_questions
Quality:
50%
✓ SciDEX
ID: open_question-642754e6-5f66-4f8a-a2c6-ef
Open Question
open
Wiki: researchers-richard-mohs
How can Clinical trials, Biomarkers signals be standardized across cohorts and sites without losing disease-stage sensitivity?
Importance Elo
1500
Field Rank
Rank #104 in researchers
Tractability
0.50
Potential Impact
0.50
Evidence Summary
Extracted from wiki page researchers-richard-mohs
Evidence Bearing On This Question
Experiment Proposal (crux): Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction — Composite index performance superiority over individual biomarkers not demonstra
partial answer for · experiment_proposal · 72%
GWAS of composite biomarker score
bears on question · experiment · 65%
Blood-Based Biomarker Panel for Early AD Detection
bears on question · experiment · 62%
Comparison of free-text clinical reports vs Mini-ICF-APP structured assessment
partial answer for · experiment · 60%
KEEPS Continuation: Long-term effects of menopausal hormone therapy on AD biomarkers
bears on question · experiment · 58%
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
bears on question · experiment · 55%
Prodromal Parkinson's Disease Biomarker Development — Early Detection for Prevention
bears on question · experiment · 52%
CXCL10 biomarker analysis for CPSP prediction
bears on question · experiment · 48%
Digital Twin-Guided Metabolic Reprogramming
bears on question · hypothesis · 45%
Experiment Index
bears on question · experiment · 40%
Pairwise Tournament History
No pairwise judgments recorded yet.
Derived Hypotheses And Proposals
Experiment Proposal (crux): Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction — Composite index performance superiority over individual biomarkers not demonstra
experiment_proposal | partial_answer_for
Digital Twin-Guided Metabolic Reprogramming
hypothesis | bears_on_question
Related Entities
Metadata
| status | open |
| _origin | {'url': None, 'type': 'internal', 'tracked_at': '2026-04-26T03:29:33.138730'} |
| field_tag | researchers |
| source_id | researchers-richard-mohs |
| sub_field | richard-mohs |
| source_kind | wiki |
| question_hash | 59d530ba09f9a0e020b25a1012ecf0300e8651d6b2121264c5ebc4380b13bf62 |
| question_text | How can Clinical trials, Biomarkers signals be standardized across cohorts and sites without losing disease-stage sensitivity? |
| importance_elo | 1500 |
| evidence_summary | Extracted from wiki page researchers-richard-mohs |
| evidence_xref_at | 2026-04-27T13:50:44.578006+00:00 |
| tractability_score | 0.5 |
| potential_impact_score | 0.5 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
11
0 supporting
0 contradicting
0 neutral